577 related articles for article (PubMed ID: 30743162)
1. Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry.
Rakaee M; Busund LR; Jamaly S; Paulsen EE; Richardsen E; Andersen S; Al-Saad S; Bremnes RM; Donnem T; Kilvaer TK
Neoplasia; 2019 Mar; 21(3):282-293. PubMed ID: 30743162
[TBL] [Abstract][Full Text] [Related]
2. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
Li Z; Maeda D; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Konno H; Saito H; Minamiya Y; Goto A
Lung Cancer; 2018 Sep; 123():127-135. PubMed ID: 30089583
[TBL] [Abstract][Full Text] [Related]
3. Spatial interaction and functional status of CD68
Liu X; Zhang Z; Yuan J; Yu J; Chen D
Front Immunol; 2024; 15():1396719. PubMed ID: 38799432
[TBL] [Abstract][Full Text] [Related]
4. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time.
Ma J; Liu L; Che G; Yu N; Dai F; You Z
BMC Cancer; 2010 Mar; 10():112. PubMed ID: 20338029
[TBL] [Abstract][Full Text] [Related]
5. Distribution of M1 and M2 macrophages in tumor islets and stroma in relation to prognosis of non-small cell lung cancer.
Jackute J; Zemaitis M; Pranys D; Sitkauskiene B; Miliauskas S; Vaitkiene S; Sakalauskas R
BMC Immunol; 2018 Jan; 19(1):3. PubMed ID: 29361917
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: A systemic review and meta-analysis.
Mei J; Xiao Z; Guo C; Pu Q; Ma L; Liu C; Lin F; Liao H; You Z; Liu L
Oncotarget; 2016 Jun; 7(23):34217-28. PubMed ID: 27144518
[TBL] [Abstract][Full Text] [Related]
7. Antibody combinations for optimized staining of macrophages in human lung tumours.
Frafjord A; Skarshaug R; Hammarström C; Stankovic B; Dorg LT; Aamodt H; Woldbaek PR; Helland Å; Brustugun OT; Øynebråten I; Corthay A
Scand J Immunol; 2020 Jul; 92(1):e12889. PubMed ID: 32299134
[TBL] [Abstract][Full Text] [Related]
8. Interstitial tumor-associated macrophages combined with tumor-derived colony-stimulating factor-1 and interleukin-6, a novel prognostic biomarker in non-small cell lung cancer.
Pei BX; Sun BS; Zhang ZF; Wang AL; Ren P
J Thorac Cardiovasc Surg; 2014 Oct; 148(4):1208-1216.e2. PubMed ID: 24907005
[TBL] [Abstract][Full Text] [Related]
9. Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma.
Zheng X; Weigert A; Reu S; Guenther S; Mansouri S; Bassaly B; Gattenlöhner S; Grimminger F; Pullamsetti S; Seeger W; Winter H; Savai R
Cancer Res; 2020 Oct; 80(20):4414-4425. PubMed ID: 32699134
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients.
Hwang I; Kim JW; Ylaya K; Chung EJ; Kitano H; Perry C; Hanaoka J; Fukuoka J; Chung JY; Hewitt SM
J Transl Med; 2020 Nov; 18(1):443. PubMed ID: 33228719
[TBL] [Abstract][Full Text] [Related]
11. CC-Chemokine Ligand 18 Is an Independent Prognostic Marker in Lymph Node-positive Non-small Cell Lung Cancer.
Schmid S; Csanadi A; Kozhuharov N; Tchudjin M; Kayser C; Rawluk J; Passlick B; Werner M; Prasse A; Kayser G
Anticancer Res; 2018 Jul; 38(7):3913-3918. PubMed ID: 29970512
[TBL] [Abstract][Full Text] [Related]
12. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival.
Ohri CM; Shikotra A; Green RH; Waller DA; Bradding P
Eur Respir J; 2009 Jan; 33(1):118-26. PubMed ID: 19118225
[TBL] [Abstract][Full Text] [Related]
13. Macrophages-based immune-related risk score model for relapse prediction in stage I-III non-small cell lung cancer assessed by multiplex immunofluorescence.
Wu XR; Peng HX; He M; Zhong R; Liu J; Wen YK; Li CC; Li JF; Xiong S; Yu T; Zheng HB; Chen YH; He JX; Liang WH; Cai XY
Transl Lung Cancer Res; 2022 Apr; 11(4):523-542. PubMed ID: 35529784
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer.
Sumitomo R; Hirai T; Fujita M; Murakami H; Otake Y; Huang CL
Lung Cancer; 2019 Oct; 136():136-144. PubMed ID: 31499335
[TBL] [Abstract][Full Text] [Related]
15. M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma.
Falleni M; Savi F; Tosi D; Agape E; Cerri A; Moneghini L; Bulfamante GP
Melanoma Res; 2017 Jun; 27(3):200-210. PubMed ID: 28272106
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
Yuan X; Zhang J; Li D; Mao Y; Mo F; Du W; Ma X
Gynecol Oncol; 2017 Oct; 147(1):181-187. PubMed ID: 28698008
[TBL] [Abstract][Full Text] [Related]
17. The tissue microlocalisation and cellular expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 is correlated to clinical outcome in NSCLC.
Ohri CM; Shikotra A; Green RH; Waller DA; Bradding P
PLoS One; 2011; 6(7):e21874. PubMed ID: 21799753
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma.
Al-Shibli K; Al-Saad S; Donnem T; Persson M; Bremnes RM; Busund LT
Histopathology; 2009 Sep; 55(3):301-12. PubMed ID: 19723145
[TBL] [Abstract][Full Text] [Related]
19. Tumoral NOX4 recruits M2 tumor-associated macrophages via ROS/PI3K signaling-dependent various cytokine production to promote NSCLC growth.
Zhang J; Li H; Wu Q; Chen Y; Deng Y; Yang Z; Zhang L; Liu B
Redox Biol; 2019 Apr; 22():101116. PubMed ID: 30769285
[TBL] [Abstract][Full Text] [Related]
20. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer.
Ino Y; Yamazaki-Itoh R; Shimada K; Iwasaki M; Kosuge T; Kanai Y; Hiraoka N
Br J Cancer; 2013 Mar; 108(4):914-23. PubMed ID: 23385730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
